News About: Pharm. Affairs
First generic development of new antithrombotic drug, ‘Brilinta,’ has begun
Movements to develop the first generic of the AstraZeneca’s next-generation antithrombotic drug, Brilinta(generic name: ticagrelor), have been observed.
On the 14th, the Ministry of Food and Drug Safety approved bioe...
Novartis to give prior notice for domestic introduction of Entresto
‘Entresto,’ a Novartis’s new cardiac insufficiency drug, will be introduced in Korea.
According to the industry concerned on the 16th, Novartis has applied for the domestic approval of Entresto, a valsartan+sacubitri...
Total 18 patent cases of removals from ‘Green List’
As a part of registered patents of well-known pharmaceutical products are nullified, it was known that they were removed from the ‘Green List.’
According to the Ministry of Food and Drug Safety on the 14th, they were...
Selling prices of Cialis generics are 1/10 of the original
Competition has been fierce to occupy the generic market of ‘Cialisa’ a tadalafil-type impotency treatment, since its patent expiration on the last 4th.
157 generic products of Cialis were approved and launched in 60...
Getting close to KRW 200 billion in the Alzheimer’s dementia treatment market
The amount of laxatives for Alzheimer’s dementia symptoms has been annually increased by double figures. The last year’s prescriptions are expected to form a KRW 200 billion market soon as exceeding KRW 180 billion pr...
Price of Gilead’s Sovaldi expected at KRW 30 million in negotiation
The company seems to drop greediness. It was observed that Gilead will decide the price of ‘Sovaldi,’ a hepatitis C treatment approved domestically on the last 10th, at a lower price than the ones in other countries.
...
Approval of Sovaldi triggered active new drug competition
‘Sovaldi(sofosbuvir), a hepatitis C treatment, has been approved.
According to the industry concerned on the 11th, Gilead Sciences Korea’s Sovaldi has acquired approval from Ministry of Food and Drug Safety(MFDS) on ...
At the first symposium, “This will be a chance of exchange with North Korea’s academia”
A symposium related to the North Korea’s pharmaceutical system, which has been delayed once due to the spread of MERS, will be held on the 18th next week. Contents of the symposium have also been improved by participa...
‘Belviq’ has rapidly become a leaderThe power of an obesity treatment approved by the FDA was tremendous. Belviq, an obesity treatment first launched by Ildong Pharmaceutical on March, recorded KRW 6 billion sales...
|
‘Fierce new drugs,’ Belviq and Xtandi, reserved to be blockbusters
Recently-launched new products have shown smooth starts. In particular, Belviq, an obesity treatment, and ‘Xtandi,’ a prostate cancer treatment, have already notified the market of becoming KRW 10 billion blockbusters...
